Table 3.
Independent risk factors for progression to ESRD in the multivariate Cox regression analysis.
| Baseline data | All patients | Non-treatment group | Treatment group |
|---|---|---|---|
| Clinical findings | |||
| Age (per 10 years increase) | 0.87, 0.72–1.04, P = 0.1249 | 0.82, 0.64–1.06, P = 0.1386 | 0.86, 0.63–1.16, P = 0.3320 |
| Sex (male vs female) | 1.42, 0.92–2.19, P = 0.1247 | 1.73, 1.03–2.90, P = 0.0394 | 1.30, 0.65–2.58, P = 0.4564 |
| BMI (per 1 kg/m2 increase) | 0.96, 0.89–1.04, P = 0.3500 | 1.00, 0.91–1.11, P = 0.9337 | 0.96, 0.84–1.08, p = 0.4851 |
| MAP (per 10 mmHg increase) | 1.30, 1.09–1.57, P = 0.0046 | 1.27, 0.99–1.62, P = 0.0611 | 1.24, 0.90–1.70, P = 0.1822 |
| Laboratory findings | |||
| eGFR (per 30 ml/min decrease) | 2.62, 1.90–3.62, P < 0.0001 | 2.30, 1.48–360, P = 0.0002 | 3.07, 1.80–5.30, P < 0.0001 |
| U-Prot (per 0.5 g/day increase) | 1.36, 1.24–1.48, P < 0.0001 | 1.41, 1.25–1.60, P < 0.0001 | 1.46, 1.25–1.70, P < 0.0001 |
| U-RBC (per 25/HPF increase) | 0.99, 0.87–1.12, P = 0.8553 | 1.12, 0.98–1.30, P = 0.1525 | 0.86, 0.67–1.08, P = 0.2070 |
| Histological findings | |||
| M1 (vs. M0) | 0.91, 0.62–1.34, P = 0.6432 | 0.84, 0.65–1.37, P = 0.4837 | 1.22, 0.62–2.49, P = 0.5766 |
| E1 (vs. E0) | 0.93, 0.58–1.49, P = 0.7605 | 0.88, 0.49–1.56, P = 0.6567 | 1.12, 0.48–2.71, P = 0.7974 |
| S1 (vs. S0) | 1.33, 0.80–2.19, P = 0.2667 | 1.75, 0.91–3.39, P = 0.0936 | 0.84, 0.39–2.00, P = 0.6719 |
| T1-2 (per 1 grade increase) | 1.48, 1.10–1.99, P = 0.0085 | 1.37, 0.92–2.02, P = 0.1183 | 1.76, 1.05–2.92, P = 0.0287 |
| C1-2 (per 1 grade increase) | 0.95, 0.65–1.38, P = 0.7895 | 1.58, 0.98–2.56 P = 0.0628 | 0.76, 0.36–1.52, P = 0.4505 |
BMI body mass index, MAP mean arterial pressure, TP serum total protein, eGFR estimated glomerular filtration rate, U-Prot urinary protein excretion, U-RBC urinary red blood cells, M mesangial hypercellularity, E endocapillary hypercellularity, S segmental sclerosis, T interstitial fibrosis/tubular atrophy, C crescents.